# Contact RX MT2 — Melanotan 2 Research Digest

> Contact the RX MT2 editorial team — corrections, citation issues, or editorial correspondence about the Melanotan 2 research digest.

RX MT2 is an independent editorial digest of the Melanotan 2 (MT-II) research literature. We welcome correspondence on the following topics:

**Citation corrections.** If a citation is broken, the DOI has changed, or a study has been retracted, we want to know. Editorial integrity means the reference list stays current.

**Factual corrections.** If a finding is misrepresented or a numerical claim does not match the source, send us the specific citation and the discrepancy.

**New research.** If a relevant peer-reviewed paper has been published that we have not covered, send the PMID or DOI. We prioritize Phase I/II human trials, pharmacovigilance publications, and systematic reviews.

We do not answer questions about personal use, sourcing, dosing recommendations, or clinical consultations. This site is an editorial project, not a healthcare service. Questions of that nature should be directed to a licensed medical professional.

RX MT2 does not provide medical advice, dosing recommendations, or product sourcing information. All content on this site is editorial commentary on publicly available peer-reviewed research. MT-II has not been approved for human use by any regulatory authority.

---

An editorial reading of the peer-reviewed Melanotan 2 record — Phase I trials, preclinical mechanism studies, and pharmacovigilance case reports, indexed to source.